# US 2024/0002878 A1 · A universal platform to enhance crispr-based gene editing for in vivo therapies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002878 A1
- Document ID: US20240002878A1
- Status: Published application
- Kind: A1
- Application number: 18/327,373
- Filed: 2023-06-01
- Published: 2024-01-04
- Earliest claimed: 2017-06-26
- Assignees: Arizona Board of Regents on behalf of Arizona State University
- Applicants: Arizona Board of Regents On Behalf of Arizona State University
- Inventors: Samira Kiani; Mo Reza Ebrahimkhani; Jennifer Chapman
- Web page: https://patentgrep.com/patent/US20240002878A1

## CPC

- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/85: for animal cells
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- C12N 15/62: DNA sequences coding for fusion proteins
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N 15/907: {in mammalian cells}
- C12N 2310/128: processing or releasing ribozyme
- C12N 2310/16: Aptamers
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2501/12: Hepatocyte growth factor [HGF]
- C12N 2501/405: Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Aspects of the disclosure relate to methods and synthetic regulatory systems for more efficient nuclease-mediated homology-directed repair (HDR). In particular, provided herein are methods for more efficient in vivo and in vitro HDR-based gene editing where the methods comprise introducing into a cell a synthetic regulatory system comprising Cas nuclease, guide RNAs (gRNAs) having various lengths and configured to target distinct nucleotide sequences for simultaneous transcriptional repression (or activation) and genome editing via double stranded break and use of a donor nucleic acid molecule as a template for repair.

## Claims

### Claim 1

A method for efficient Homology-Directed repair (HDR)-based gene editing, the method comprising introducing into an isolated recombinant host cell:
(a) at least one truncated guide RNA (gRNA) of 15 or less nucleotides (nt) in length complementary to at least a portion of a nucleotide sequence encoding a non-homologous end joining (NHEJ)-associated enzyme selected from the group consisting of DNA ligase IV (LigIV), XRCC4, XRCC5 (KU80), and XRCC6 (KU70);
(b) at least one gRNA of 16 or greater nt in length that is complementary to at least a portion of a gene targeted for genetic editing; and
(c) an RNA aptamer that recruits methyl-CpG binding protein (MecP2);
wherein the at least one truncated gRNA, the at least one gRNA, and the aptamer comprise a single amplicon; and
wherein the host cell expresses a catalytically active Cas9 nuclease.

### Claim 2 (depends on 1)

The method of claim 1, wherein the Cas9 nuclease is fused to a fusion repression domain comprising Kruppel associated box (KRAB) repression domain and MecP2 (KRAB-MecP2).

### Claim 3 (depends on 1)

The method of claim 1, wherein the NHEJ-associated enzyme is LigIV.

### Claim 4 (depends on 3)

The method of claim 3, wherein the truncated gRNA comprises a sequence selected from the group consisting of SEQ ID NOs: 9, 10, and 11.

### Claim 5 (depends on 1)

The method of claim 1, wherein the amplicon further comprises a truncated activating gRNA complementary to at least a portion of a nucleotide sequence encoding cell cycle progression factor.

### Claim 6 (depends on 5)

The method of claim 5, wherein the at least one cell cycle progression factor is selected from the group consisting of hepatocyte growth factor (HGF), Cyclin A1, Cyclin A2, Cyclin B1, Cyclin E1, skp2, CtIP, cyclin dependent kinase 2 (CDK2), and Geminin (GMNN).

### Claim 7 (depends on 5)

The method of claim 5, wherein the truncated activating gRNA further comprises a ligand-responsive riboswitch.

### Claim 8 (depends on 7)

The method of claim 7, wherein the ligand-responsive riboswitch is a tetracycline riboswitch or theophylline riboswitch.
